Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone tells us about the design and outcomes of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma from ASH 2019.
Advertisement